Akebia says new Vafseo dosing patent is listed in FDA Orange Book

Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.

AKBA

0.00
  • Akebia Therapeutics added a new Orange Book-listed U.S. patent for Vafseo (vadadustat), extending listed protection for the drug out to 2036.
  • U.S. Patent No. 12,569,474 covers once-daily dosing for CKD-related anemia in dialysis patients; it expires in June 2034.
  • A separate vadadustat composition-of-matter patent was cleared for a potential 5-year term extension to mid-2032, pending a USPTO certificate.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606100800PRIMZONEFULLFEED9734817) on June 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.